

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1PW

Applicant:

Steven D. Girouard et al.

Title:

METHOD AND APPARATUS FOR DEVICE CONTROLLED GENE EXPRESSION

Docket No.:

279.696US1

Serial No.: 10/788,906

Filed:

February 27, 2004

Examiner:

Jessica L. Reidel

Group Art Unit: 3766

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):

X Return postcard.

X Communication Concerning Related Applications (1 pg.).

 $\overline{\underline{X}}$ Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (1 pg.), and copies of 13 cited documents.

Please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

Customer Number 21186

Atty: Janet E. Embreson Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 25 day of February, 2006.

Name

Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

(GENERAL)

S/N 10/788,906

MAR 0 3 2006

PATENT

TATES PATENT AND TRADEMARK OFFICE

METHOD AND APPARATUS FOR DEVICE CONTROLLED GENE

Applicant:

Gifouard et al. Steven D.

Examiner: Jessica L. Reidel

Serial No.:

10/788,906

Group Art Unit: 3766

Filed:

February 27, 2004

Docket: 279.696US1

Title:

EXPRESSION

COMMUNICATION CONCERNING RELATED APPLICATIONS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Applicants would like to bring to the Examiner's attention the following related applications in the above-identified patent application:

Serial/Patent No.

Filing Date/Issue Date

Attorney Docket

Title

11/276,077

February 13, 2006

279.A01US1

METHOD AND APPARATUS FOR HEAT OR ELECTROMAGNETIC CONTROL OF GENE EXPRESSION

Continuations and divisionals may be later filed on the cases listed above, or cited to the Examiner in any previous Communication Concerning Related Applications. Applicants request that the Examiner review all continuations and divisionals of the above-listed or previously-cited patent applications before allowing the claims of the present patent application.

Respectfully submitted,

STEVEN D. GIROUARD ET AL.

By Applicants' Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date HOWWY 25

Janet E. Embretson

Reg. No. 39.66:

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, op this day of February, 2006.

S/N 10/788,906 **PATENT**

TATES PATENT AND TRADEMARK OFFICE

Applicant:

Steven D. Girouard et al.

Examiner:

Jessica L. Reidel

Serial No.:

10/788,906

Group Art Unit:

3766

Filed:

February 27, 2004

Docket:

279.696US1

Title:

METHOD AND APPARATUS FOR DEVICE CONTROLLED GENE

EXPRESSION

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

Filing Date: February 27, 2004

Title: METHOD AND APPARATUS FOR DEVICE CONTROLLED GENE EXPRESSION

Page 2 Dkt: 279.696US1

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted, STEVEN D. GIROUARD ET AL.

By their Representatives, SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6952

Date telly May 28, 2016

Jahet E. Embretson Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to. Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450,

Alexandria, VA 22313-1450, on this 20 day of February, 2006.

Jama

Signature

PTO/SB/084(10-01)
Approved for use through 10/31/20/2, OMB 651-0031
US Patient & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE 10/788,906 **Application Number** STATEMENT BY APPLICANT Use as many sheets as necessar February 27, 2004 Filing Date **First Named Inventor** Girouard, Steven 3766 **Group Art Unit** Reidel, Jessica **Examiner Name** Attorney Docket No: 279.696US1 Sheet 1 of 1

US PATENT DOCUMENTS							
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate			
	US-2002/0055705A1	05/09/2002	Talpade, Dnyanesh, et al.	10/08/1999			
	US-2002/0183682A1	12/05/2002	Darvish, Nissim, et al.	06/14/2002			
	US-2003/0026784A1	02/06/2003	Koch, Walter J., et al.	06/28/2002			
	US-2003/0045830A1	03/06/2003	de Bizemont, Therese, et al.	04/17/2001			
	US-2006/0015146A1	01/19/2006	Girouard, S. D., et al.	07/14/2004			
	US-5,387,419	02/07/1995	Levy, R. J., et al.	03/26/1993			
	US-5,944,710	08/31/1999	Dev, S. B., et al.	06/24/1996			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²			
	WO-9815317	04/16/1998	Prutchi, David, et al.				
	WO-9904851	02/04/1999	Shapland, J. E., et al.				
	WO-9936563	07/22/1999	Walsh, Robert, et al.				

	OTI	HER DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		"International Search Report for Application No. PCT/US2005/006069, date mailed October 20, 2005", 19 Pages	
		AVITALL, B., "Iontophoretic transmyocardial drug delivery. A novel approach to antiarrhythmic drug therapy.", Circulation, 85(4), (Apr., 1992),1582-93	
		BOVENBERG, W. A., et al., "Expression of recombinant human insulin-like growth factor I in mammalian cells", Mol Cell Endocrinol., 74(1), (Nov. 12, 1990), 45-59.	
	•	FREY, NORBERT, et al., "Decoding calcium signals involved in cardiac growth and function", Nature Medicine 6(11), (2000), 1221-1227	
		GUNATILLAKE, PATHIRAJA A., et al., "Biodegradable Synthetic Polymers for Tissue Engineering", European Cells and Materials 5, (2003), 1-16	
		KANIKKANNAN, NARAYANASAMY, "Iontophoresis-Based Transdermal Delivery Systems", Biodrugs 16(5), (2002), 339-347	
		MACGOWAN, G. A., et al., "New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies", <u>Ir J Med Sci., 171(2)</u> , (AprJun., 2002), 99-104	
		OUDIT, GAVIN Y., et al., "The Molecular Physiology of the Cardiac Transient Outward Potassium Current (Ito) in Normal and Diseased Myocardium", I Mol Cell Cardiol 33, (2001), 851-872	
		RECER, P., "Researchers find first heart attack gene", AP Science News, Science: www.science.org, (2003)	
		WURM, F. M., et al., "Inducible overproduction of the mouse c-myc protein in mammalian cells", Proc Natl Acad Sci U S A., 83(15), (Aug., 1986), 5414-8	

DATE CONSIDERED EXAMINER